Key facts
- Verisian’s last known valuation is $18.1M (May 2025).
- It has raised $5.6M; the latest was Seed Round ($4.3M) in May 2025.
- Notable investors include Seedcamp, Cambridge Angels, Dimension (United States), SuperSeed.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Verisian
- ·The full record, as it builds
Funding rounds
No funding rounds for Verisian are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Verisian
Provider of clinical research analytics platforms designed to improve transparency and decision-making in trial evaluation. The company offers tools that support real-time monitoring, standardized data integration, and collaborative analysis aligned with regulatory frameworks, enabling researchers and public health authorities to reduce submission delays, minimize errors, and accelerate access to safer, more effective treatments for patients with serious medical conditions.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2023
- Employees
- 12
- Website
- verisian.com/
- Ownership
- Privately Held (backing)
Verisian doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Verisian shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Verisian in its N-PORT filings yet. We sweep new filings monthly.